MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Regulation FD Disclosure

MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Story continues below

On October 1, 2018, Microbot Medical Inc. (the “Registrant”) issued a press release announcing that Harel Gadot, Chief Executive Officer, President and Chairman of the Company, is scheduled to present on Tuesday, October 2, 2018 at 1:30 P.M. (ET) at the Ladenburg Thalmann Healthcare Conference, at the Sofitel Hotel in New York City. A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the ‘Investors’ section, under ‘Presentations and Resources’ of the Company’s website at www.microbotmedical.com. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company is also furnishing presentation materials as Exhibit 99.2 to this Current Report on Form 8-K. The Company is not undertaking to update this presentation.

The information in this Item 7.01 and in Exhibits 99.1 and 99.2 of Item 9.01 is being furnished to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibits 99.1 and 99.2 of Item 9.01.

Item 9.01 Financial Statements and Exhibits.


Microbot Medical Inc. Exhibit
EX-99.1 2 ex99-1.htm     Microbot Medical Inc. to Present at the Ladenburg Thalmann Healthcare Conference   Hingham,…
To view the full exhibit click here

About MICROBOT MEDICAL INC. (NASDAQ:MBOT)

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

An ad to help with our costs